Heparin-induced thrombocytopenia in newborns: experience at a pediatric hospital and a literature review.
child
heparin
heparin-induced thrombocytopenia
incidence
newborns
thrombocytopenia
thrombosis
Journal
Research and practice in thrombosis and haemostasis
ISSN: 2475-0379
Titre abrégé: Res Pract Thromb Haemost
Pays: United States
ID NLM: 101703775
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
25
05
2023
revised:
08
08
2023
accepted:
16
09
2023
medline:
11
12
2023
pubmed:
11
12
2023
entrez:
11
12
2023
Statut:
epublish
Résumé
Heparin-induced thrombocytopenia (HIT) is a rare, difficult-to-diagnose, and potentially serious adverse drug reaction with thrombotic complications. Even though the immune system is still immature during the neonatal period, HIT has been described in newborns with reporting rates ranging from 0% to 2.3%. Therefore, it is important to clarify the risk of HIT in newborns because it can affect the management and monitoring of heparin treatment. The objectives of the present study were to review the literature and determine the incidence of HIT after cardiac surgery in newborns in our pediatric hospital. We searched the literature from 1992 to 2021 for reports of HIT in newborns. Four raters then analyzed all the literature reports on HIT and classified them as "likely," "uncertain," or "unlikely." We also determined the incidence of HIT among newborns having undergone cardiac surgery in our pediatric hospital. Eleven population-based studies and 12 case reports on suspected HIT in 17 newborns were reviewed. One study reported HIT in 14 out of 930 (1.5%) heparin-treated newborns, but the other studies ( We conclude that the incidence of HIT in newborns has been overestimated in the literature.
Sections du résumé
Background
UNASSIGNED
Heparin-induced thrombocytopenia (HIT) is a rare, difficult-to-diagnose, and potentially serious adverse drug reaction with thrombotic complications. Even though the immune system is still immature during the neonatal period, HIT has been described in newborns with reporting rates ranging from 0% to 2.3%. Therefore, it is important to clarify the risk of HIT in newborns because it can affect the management and monitoring of heparin treatment.
Objectives
UNASSIGNED
The objectives of the present study were to review the literature and determine the incidence of HIT after cardiac surgery in newborns in our pediatric hospital.
Methods
UNASSIGNED
We searched the literature from 1992 to 2021 for reports of HIT in newborns. Four raters then analyzed all the literature reports on HIT and classified them as "likely," "uncertain," or "unlikely." We also determined the incidence of HIT among newborns having undergone cardiac surgery in our pediatric hospital.
Results
UNASSIGNED
Eleven population-based studies and 12 case reports on suspected HIT in 17 newborns were reviewed. One study reported HIT in 14 out of 930 (1.5%) heparin-treated newborns, but the other studies (
Conclusion
UNASSIGNED
We conclude that the incidence of HIT in newborns has been overestimated in the literature.
Identifiants
pubmed: 38077818
doi: 10.1016/j.rpth.2023.102214
pii: S2475-0379(23)00472-7
pmc: PMC10704508
doi:
Types de publication
Journal Article
Langues
eng
Pagination
102214Informations de copyright
© 2023 The Authors.
Références
Anaesth Crit Care Pain Med. 2020 Apr;39(2):291-310
pubmed: 32299756
Nat Rev Immunol. 2004 Jul;4(7):553-64
pubmed: 15229474
Semin Thorac Cardiovasc Surg Pediatr Card Surg Annu. 2004;7:155-71
pubmed: 15283365
N Engl J Med. 2015 Jul 16;373(3):252-61
pubmed: 26176382
J Thromb Haemost. 2004 Nov;2(11):1882-8
pubmed: 15550015
Anesth Analg. 2008 Aug;107(2):371-8
pubmed: 18633010
Blood. 2000 Sep 1;96(5):1703-8
pubmed: 10961867
J Extra Corpor Technol. 2012 Jun;44(2):69-74
pubmed: 22893986
Cochrane Database Syst Rev. 2005 Oct 19;(4):CD002774
pubmed: 16235300
Ann Pharmacother. 2003 Feb;37(2):229-33
pubmed: 12549954
Blood. 2005 Oct 15;106(8):2710-5
pubmed: 15985543
Maedica (Bucur). 2016 Mar;11(1):68-71
pubmed: 28465755
J Thromb Haemost. 2013 Apr;11(4):660-9
pubmed: 23350790
J Extra Corpor Technol. 2011 Mar;43(1):5-12
pubmed: 21449228
J Thromb Haemost. 2010 Jan;8(1):30-6
pubmed: 19793190
Am J Hematol. 2015 Jun;90(6):564-72
pubmed: 25775976
Pediatrics. 2002 Jan;109(1):E10
pubmed: 11773578
Blood Rev. 2008 Jul;22(4):173-86
pubmed: 18433954
J Thromb Haemost. 2006 Apr;4(4):759-65
pubmed: 16634744
J Pediatr Surg. 1997 May;32(5):768-71
pubmed: 9165476
Scand J Immunol. 2011 Jan;73(1):53-8
pubmed: 21129003
Thromb Res. 2006;118(1):123-35
pubmed: 16709481
J Pediatr Hematol Oncol. 2007 Apr;29(4):265-8
pubmed: 17414571
Blood Adv. 2018 Nov 27;2(22):3360-3392
pubmed: 30482768
Arch Dis Child Fetal Neonatal Ed. 2010 Jul;95(4):F252-7
pubmed: 20530110
Early Hum Dev. 2011 Feb;87(2):67-72
pubmed: 21123010
Pediatrics. 2009 Dec;124(6):e1095-100
pubmed: 19917581
Thromb Haemost. 2016 Apr;115(4):752-61
pubmed: 26467272
J Thromb Haemost. 2021 Aug;19(8):1959-1972
pubmed: 33872452
Cochrane Database Syst Rev. 2002;(4):CD002774
pubmed: 12519576
Acta Paediatr. 2002;91(12):1350-6
pubmed: 12578294
Thromb Haemost. 2004 Apr;91(4):719-24
pubmed: 15045133
Congenit Heart Dis. 2008 Jul-Aug;3(4):299-302
pubmed: 18715467
J Pak Med Assoc. 2009 Jun;59(6):345-50
pubmed: 19534365
J Immunol. 2007 Jan 15;178(2):1180-8
pubmed: 17202383
Pediatr Crit Care Med. 2007 Jul;8(4):358-61
pubmed: 17545932
Circulation. 1999 May 18;99(19):2530-6
pubmed: 10330384
Pediatrics. 2007 Jan;119(1):e284-91
pubmed: 17200252
Ann Thorac Surg. 2006 Jun;81(6):S2355-9
pubmed: 16731103
J Pediatr. 2015 Jan;166(1):144-50
pubmed: 25444534
Blood. 2010 Mar 4;115(9):1797-803
pubmed: 19965682
Clin Appl Thromb Hemost. 2004 Oct;10(4):335-9
pubmed: 15497019
J Thromb Haemost. 2018 Feb;16(2):196-208
pubmed: 29316202
Ann Thorac Surg. 2003 Aug;76(2):638-48
pubmed: 12902132
J Extra Corpor Technol. 2004 Jun;36(2):178-81
pubmed: 15334762
Neonatal Netw. 2005 Sep-Oct;24(5):33-7
pubmed: 16279053
J Vasc Surg. 1992 Feb;15(2):306-11; discussion 311-2
pubmed: 1735891